CN111065396A - 促进毛发生长和治疗毛发缺损或过度毛发脱落 - Google Patents

促进毛发生长和治疗毛发缺损或过度毛发脱落 Download PDF

Info

Publication number
CN111065396A
CN111065396A CN201880057079.8A CN201880057079A CN111065396A CN 111065396 A CN111065396 A CN 111065396A CN 201880057079 A CN201880057079 A CN 201880057079A CN 111065396 A CN111065396 A CN 111065396A
Authority
CN
China
Prior art keywords
minoxidil
range
hair
concentration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880057079.8A
Other languages
English (en)
Chinese (zh)
Inventor
罗德尼·辛克莱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samson Clinical Pty Ltd
Original Assignee
Samson Clinical Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902722A external-priority patent/AU2017902722A0/en
Application filed by Samson Clinical Pty Ltd filed Critical Samson Clinical Pty Ltd
Publication of CN111065396A publication Critical patent/CN111065396A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
CN201880057079.8A 2017-07-12 2018-07-12 促进毛发生长和治疗毛发缺损或过度毛发脱落 Pending CN111065396A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902722A AU2017902722A0 (en) 2017-07-12 Promoting hair growth and treatment of hair loss or excessive hair shedding
AU2017902722 2017-07-12
PCT/AU2018/050719 WO2019010535A1 (en) 2017-07-12 2018-07-12 STIMULATION OF HAIR GROWTH AND TREATMENT OF HAIR FALL OR EXCESSIVE ALOPECIA

Publications (1)

Publication Number Publication Date
CN111065396A true CN111065396A (zh) 2020-04-24

Family

ID=65001077

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880057079.8A Pending CN111065396A (zh) 2017-07-12 2018-07-12 促进毛发生长和治疗毛发缺损或过度毛发脱落

Country Status (10)

Country Link
US (2) US20190269684A1 (cg-RX-API-DMAC7.html)
EP (1) EP3651769B1 (cg-RX-API-DMAC7.html)
JP (2) JP7191927B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240064747A (cg-RX-API-DMAC7.html)
CN (1) CN111065396A (cg-RX-API-DMAC7.html)
AU (2) AU2018250398B2 (cg-RX-API-DMAC7.html)
CA (1) CA3069336A1 (cg-RX-API-DMAC7.html)
ES (1) ES2909395T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202000124PA (cg-RX-API-DMAC7.html)
WO (1) WO2019010535A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112691187A (zh) * 2020-12-30 2021-04-23 深圳新发源植物科技发展有限公司 一种用于防止额前脱发的缓释膜及其制备方法
CN116803391A (zh) * 2021-06-17 2023-09-26 南京韦尔优众医药有限公司 Wez系列化合物在制备预防或/和治疗脱发产品中的用途
CN120417906A (zh) * 2022-10-25 2025-08-01 韦瑞德米克斯公司 用于改性释放米诺地尔的组合物和使用方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732075A (en) 2014-10-29 2022-09-30 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding
GB2596942B (en) 2019-02-27 2023-05-10 Samson Clinical Pty Ltd Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding
WO2021178871A1 (en) 2020-03-05 2021-09-10 University Of Miami Cannabidiol nanodrug formulations and methods for use the same
EP4539816A4 (en) * 2023-09-01 2025-07-23 Follea Int COMPOSITIONS AND METHODS FOR AN ORALLY ADMINISTERED MINOXIDIL SUPPLEMENT FOR THE TREATMENT OF ALOPECIA
KR20260065905A (ko) * 2023-09-08 2026-05-11 수조우 킨터 제약회사(주) 안드로겐 수용체 억제제/길항제를 함유하는 약학 조성물, 방법 및 용도
GB2638418A (en) * 2024-02-21 2025-08-27 Novumgen Ltd An orodispersible tablet of spironolactone and its process of preparation
WO2026062695A1 (en) * 2024-09-17 2026-03-26 Shah Atul K Toothpaste for body disorders

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
WO2007023396A2 (en) * 2005-05-09 2007-03-01 Foamix Ltd. Vasoactive kit and composition and uses thereof
US20070166362A1 (en) * 2004-10-07 2007-07-19 Shuji Sakuma Transdermal and transmucosal preparations
WO2010036947A2 (en) * 2008-09-27 2010-04-01 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
AU2011100917A4 (en) * 2011-07-26 2011-09-01 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2012140252A1 (en) * 2011-04-15 2012-10-18 Bionanoplus, S.L. Nanoparticles comprising esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
WO2016065426A1 (en) * 2014-10-29 2016-05-06 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
JP2009091325A (ja) * 2007-10-11 2009-04-30 Rohto Pharmaceut Co Ltd 育毛剤
US9561224B1 (en) * 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
WO1999040898A2 (en) * 1998-02-12 1999-08-19 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
US20070166362A1 (en) * 2004-10-07 2007-07-19 Shuji Sakuma Transdermal and transmucosal preparations
WO2007023396A2 (en) * 2005-05-09 2007-03-01 Foamix Ltd. Vasoactive kit and composition and uses thereof
WO2010036947A2 (en) * 2008-09-27 2010-04-01 Jina Pharmaceuticals, Inc. Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof
WO2012140252A1 (en) * 2011-04-15 2012-10-18 Bionanoplus, S.L. Nanoparticles comprising esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917A4 (en) * 2011-07-26 2011-09-01 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) * 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
WO2016065426A1 (en) * 2014-10-29 2016-05-06 Samson Clinical Pty Ltd Detection and treatment of excessive hair shedding

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112691187A (zh) * 2020-12-30 2021-04-23 深圳新发源植物科技发展有限公司 一种用于防止额前脱发的缓释膜及其制备方法
CN116803391A (zh) * 2021-06-17 2023-09-26 南京韦尔优众医药有限公司 Wez系列化合物在制备预防或/和治疗脱发产品中的用途
CN120417906A (zh) * 2022-10-25 2025-08-01 韦瑞德米克斯公司 用于改性释放米诺地尔的组合物和使用方法

Also Published As

Publication number Publication date
AU2018250398B2 (en) 2019-02-28
WO2019010535A1 (en) 2019-01-17
AU2019203438A1 (en) 2019-06-06
AU2018250398A1 (en) 2019-01-31
ES2909395T3 (es) 2022-05-06
KR20240064747A (ko) 2024-05-13
JP2023016964A (ja) 2023-02-02
CA3069336A1 (en) 2019-01-17
SG11202000124PA (en) 2020-02-27
US20190269684A1 (en) 2019-09-05
EP3651769A1 (en) 2020-05-20
JP7191927B2 (ja) 2022-12-19
EP3651769B1 (en) 2022-01-05
US20250064807A1 (en) 2025-02-27
KR102663164B1 (ko) 2024-05-07
NZ760579A (en) 2024-09-27
EP3651769A4 (en) 2021-04-21
JP2020527146A (ja) 2020-09-03
BR112020000508A2 (pt) 2020-07-14
KR20200028403A (ko) 2020-03-16

Similar Documents

Publication Publication Date Title
US20250064807A1 (en) Promoting Hair Growth and Treatment of Hair Loss or Excessive Hair Shedding
JP5537943B2 (ja) 速崩壊性固形製剤
TWI399223B (zh) 奧美沙坦酯及氨氯地平之固體劑型
AU2017203009B2 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
US20250381192A1 (en) Treatment of Autoimmune Disease
JP2003533465A (ja) 迅速崩壊固体経口投与形態
JP2014513685A (ja) 薬物送達システム
JP2005506987A (ja) 感覚的に許容される口内崩壊性組成物
CN115998740A (zh) 毛发过度脱落的检测和治疗
JP2021121645A (ja) １５β−ヒドロキシ−酢酸オサテロンの結晶多形
WO2014209022A1 (en) Chewable tablet formulation comprising tadalafil or a pharmaceutically acceptable salt thereof
AU2022200479A1 (en) Treatment of autoimmune disease
EP2646434B1 (en) Pharmaceutical compositions, dosage forms and new forms of the compound of formula (i), and methods of use thereof
JP2000502346A (ja) 皮膚炎の処置方法
WO2021171318A1 (en) Transmucosal pharmaceutical composition of levocetirizine
WO2014035355A1 (en) Pharmaceutical combination comprising idebenone and memantine
Kulkarni et al. A systematic review on oral drug delivery as a fast dissolving film to improve therapeutic effectiveness
EP2246046A1 (en) Orally disintegrating olanzapine tablet
JP5563841B2 (ja) 薬物の不快な味をマスキングした経口医薬組成物
HK40018518B (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
HK40018518A (en) Promoting hair growth and treatment of hair loss or excessive hair shedding
BR122025006573A2 (pt) Composição dispersível
BR112020000508B1 (pt) Composição orodispersível e uso de uma composição orodispersível
HU204997B (en) Process for producing carrier system suitable for ensuring controlled biological access to dihydropyridines, as well as new oral dosage form ensuring improved biological access
Maroni et al. Pharmaceutical formulations of nimesulide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination